Market Cap 1.18B
Revenue (ttm) 655.35M
Net Income (ttm) -136.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.79%
Debt to Equity Ratio 0.70
Volume 1,194,700
Avg Vol 2,069,316
Day's Range N/A - N/A
Shares Out 113.79M
Stochastic %K 30%
Beta 0.82
Analysts Strong Sell
Price Target $26.07

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, p...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
Stonkapedia
Stonkapedia Apr. 7 at 11:44 PM
$NVCR still a POS 😂 💩
0 · Reply
scotofool
scotofool Apr. 7 at 3:29 PM
$NVCR mates this trash proper cock-up, target 7
1 · Reply
Czm514
Czm514 Apr. 6 at 3:25 PM
$NVCR Whatever came of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device” Doyle and co are desperately searching for a combo partner to bring relevance and market acceptance to Optune. Too afraid to piss off Roche and Merk?
1 · Reply
BB_88_
BB_88_ Apr. 2 at 5:52 PM
$NVCR in 3k shares
1 · Reply
BB_88_
BB_88_ Mar. 31 at 2:38 PM
$NVCR in 3k shares 10.35
1 · Reply
Do_Your_Research
Do_Your_Research Mar. 30 at 7:22 PM
$NVCR we’re gonna be setting new 52 week lows soon
2 · Reply
BB_88_
BB_88_ Mar. 30 at 3:37 PM
$NVCR in 2k shares
1 · Reply
CashflowRay
CashflowRay Mar. 29 at 5:15 PM
$NVCR DVLT is compelling because it combines three things traders almost never get in one small-cap package: a giant secular theme, proof of commercial acceleration, and a plausible path to platform status. The secular theme is RWA and data monetization, with outside market forecasts reaching $16.1T by 2030. The commercial proof is already visible in $39.1M of FY2025 revenue, 1,362% YoY growth, $30.4M of gross profit, 78% gross margin, and $49M of tokenization and technology licensing agreements signed in Q4’25. The platform angle comes from IBM-powered valuation/compliance agents plus NYIAX exchange infrastructure. This is why the story can feel bigger than many peers: if execution keeps matching the vision, DVLT may not just participate in tokenization growth, it may help define how value gets priced, scored, and traded inside that growth.
2 · Reply
Czm514
Czm514 Mar. 29 at 4:56 PM
$NVCR so to the daydream believers and all the disillusioned bag holders, what’s left? Faith that management team can sell Pax way better than Lua? With no NCCN grade or help from Panova4 data? What’s the catalyst for share price recovery? Wait two more years?
1 · Reply
DCZ
DCZ Mar. 27 at 5:06 PM
$NVCR I bought more this morning
0 · Reply
Latest News on NVCR
Novocure to Report First Quarter 2026 Financial Results

Apr 1, 2026, 7:00 AM EDT - 7 days ago

Novocure to Report First Quarter 2026 Financial Results


This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Feb 12, 2026, 6:53 AM EST - 7 weeks ago

This Biotech Stock Is Jumping 25% After Getting an FDA Boost


What's Happening With NovoCure Stock?

Feb 12, 2026, 6:15 AM EST - 7 weeks ago

What's Happening With NovoCure Stock?


Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Novocure Reports Third Quarter 2025 Financial Results


Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 6 months ago

Novocure to Report Third Quarter 2025 Financial Results


Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Novocure Announces Upcoming Investor Events


Top 3 Health Care Stocks That May Explode In July

Jul 28, 2025, 6:52 AM EDT - 9 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH


Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 9 months ago

Novocure Reports Second Quarter 2025 Financial Results


Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Novocure to Report Second Quarter 2025 Financial Results


Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2025 Financial Results


Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2025 Financial Results


Novocure to Participate in Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences


Novocure Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results


Stonkapedia
Stonkapedia Apr. 7 at 11:44 PM
$NVCR still a POS 😂 💩
0 · Reply
scotofool
scotofool Apr. 7 at 3:29 PM
$NVCR mates this trash proper cock-up, target 7
1 · Reply
Czm514
Czm514 Apr. 6 at 3:25 PM
$NVCR Whatever came of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device” Doyle and co are desperately searching for a combo partner to bring relevance and market acceptance to Optune. Too afraid to piss off Roche and Merk?
1 · Reply
BB_88_
BB_88_ Apr. 2 at 5:52 PM
$NVCR in 3k shares
1 · Reply
BB_88_
BB_88_ Mar. 31 at 2:38 PM
$NVCR in 3k shares 10.35
1 · Reply
Do_Your_Research
Do_Your_Research Mar. 30 at 7:22 PM
$NVCR we’re gonna be setting new 52 week lows soon
2 · Reply
BB_88_
BB_88_ Mar. 30 at 3:37 PM
$NVCR in 2k shares
1 · Reply
CashflowRay
CashflowRay Mar. 29 at 5:15 PM
$NVCR DVLT is compelling because it combines three things traders almost never get in one small-cap package: a giant secular theme, proof of commercial acceleration, and a plausible path to platform status. The secular theme is RWA and data monetization, with outside market forecasts reaching $16.1T by 2030. The commercial proof is already visible in $39.1M of FY2025 revenue, 1,362% YoY growth, $30.4M of gross profit, 78% gross margin, and $49M of tokenization and technology licensing agreements signed in Q4’25. The platform angle comes from IBM-powered valuation/compliance agents plus NYIAX exchange infrastructure. This is why the story can feel bigger than many peers: if execution keeps matching the vision, DVLT may not just participate in tokenization growth, it may help define how value gets priced, scored, and traded inside that growth.
2 · Reply
Czm514
Czm514 Mar. 29 at 4:56 PM
$NVCR so to the daydream believers and all the disillusioned bag holders, what’s left? Faith that management team can sell Pax way better than Lua? With no NCCN grade or help from Panova4 data? What’s the catalyst for share price recovery? Wait two more years?
1 · Reply
DCZ
DCZ Mar. 27 at 5:06 PM
$NVCR I bought more this morning
0 · Reply
scotofool
scotofool Mar. 27 at 12:39 PM
$NVCR @azerd wanker pumps rubbish, pos ceo faky dattas.$NVCR proper trash, target 7
0 · Reply
None_
None_ Mar. 27 at 2:14 AM
$NVCR https://www.oncologypipeline.com/apexonco/novocure-touts-new-pancreatic-combo
0 · Reply
azerd
azerd Mar. 26 at 6:46 PM
$NVCR So I think these results are actually pretty solid? A few thoughts on why: The TTFields + Tecentriq + Gem/Nab combo performed significantly better than the Gem/Nab standard. Notably, we know TTFields is doing the heavy lifting here because Tecentriq was explicitly trialed with a number of other treatments previously (including Gem/Nab) and it did not succeed compared to the standard of care. This gives us further evidence that TTFields is truly synergistic with Immunotherapy (I/O). We’ll see the full data later, but given what we know about this combo, it shouldn't have significant additional side effects compared to Gem/Nab alone. That means it stays differentiated from the brutal NALIRIFOX or FOLFIRINOX protocols. My understanding is that if these were Phase 3 results, this combo would likely become the Standard of Care (SOC) for the ~70% of patients who can't tolerate NALIRIFOX.
2 · Reply
Do_Your_Research
Do_Your_Research Mar. 26 at 6:04 PM
$NVCR this stock is purely about the execution of selling the product now. There is no significant trial data on the horizon for 3 years (TRIDENT is not significant). The only reason the stock price will go up now is sales in Lua, Pax, and Mya. Time to find other companies to get excited about.
1 · Reply
prismmarketview
prismmarketview Mar. 26 at 2:52 PM
$NVCR #Novocure Stock Surges on Promising Pancreatic Cancer Trial Results https://prismmarketview.com/novocure-panova-4-trial-results-for-pancreatic-cancer/
0 · Reply
Stonkapedia
Stonkapedia Mar. 26 at 2:52 PM
0 · Reply
Do_Your_Research
Do_Your_Research Mar. 26 at 2:46 PM
$NVCR they should have done the panova 4 trial in locally advanced patients
0 · Reply
Discourse
Discourse Mar. 26 at 2:26 PM
$NVCR It was rather optimistic for Panova-4 to truly move the needle but this is just sad. I'm looking to liquidate my position in full on whatever the next pop is. Hopefully the price can stay above 10 dollars so the pop I'm waiting for isn't just going from 9 dollars to 12, but it'll probably find a way to do worse than expected lol. What is everyone else feeling?
1 · Reply
Do_Your_Research
Do_Your_Research Mar. 26 at 2:04 PM
$NVCR they knew this data was weak when they started talking about other combinations months ago
0 · Reply
YoloAlfred
YoloAlfred Mar. 26 at 1:37 PM
$NVCR This wants to run.....
0 · Reply
YoloAlfred
YoloAlfred Mar. 26 at 1:32 PM
0 · Reply
Do_Your_Research
Do_Your_Research Mar. 26 at 1:19 PM
$NVCR nothing burger. I bet when the full data comes out it will show that patients wore it for an average of 10 hours per day or less. Not seeing any reason to ever buy more shares of this company
1 · Reply